Join us for a KOL Event with Belite Bio, featuring Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS (Stanford University School of Medicine) who will discuss Belite Bio’s one-year interim data from the two-year Phase 1b/2 trial of LBS-008 (aka Tinlarebant), as a potential early intervention oral treatment for Stargardt disease (STGD1) and dry age-related macular degeneration (dry AMD), which share a similar pathophysiology with STGD1.

A live Q&A session will follow.